Literature DB >> 24346431

Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma.

Kristina Y Aguilera1, Lee B Rivera, Hoon Hur, Juliet G Carbon, Jason E Toombs, Courtney D Goldstein, Michael T Dellinger, Diego H Castrillon, Rolf A Brekken.   

Abstract

There is growing evidence that antiangiogenic therapy stimulates cancer cell invasion and metastasis. However, the underlying molecular mechanisms responsible for these changes have not been fully defined. Here, we report that anti-VEGF therapy promotes local invasion and metastasis by inducing collagen signaling in cancer cells. We show that chronic VEGF inhibition in a genetically engineered mouse model of pancreatic ductal adenocarcinoma (PDA) induces hypoxia, a less differentiated mesenchymal-like tumor cell phenotype, TGF-β expression, and collagen deposition and signaling. In addition, we show that collagen signaling is critical for protumorigenic activity of TGF-β in vitro. To further model the impact of collagen signaling in tumors, we evaluated PDA in mice lacking Sparc, a protein that reduces collagen binding to cell surface receptors. Importantly, we show that loss of Sparc increases collagen signaling and tumor progression. Together, these findings suggest that collagen actively promotes PDA spread and that enhanced disease progression associated with anti-VEGF therapy can arise from elevated extracellular matrix-mediated signaling. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24346431      PMCID: PMC3944405          DOI: 10.1158/0008-5472.CAN-13-2800

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

1.  Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer.

Authors:  Sean P Dineen; Christina L Roland; Rachel Greer; Juliet G Carbon; Jason E Toombs; Puja Gupta; Nabeel Bardeesy; Haizhou Sun; Noelle Williams; John D Minna; Rolf A Brekken
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

2.  TGF-β and αvβ6 integrin act in a common pathway to suppress pancreatic cancer progression.

Authors:  Aram F Hezel; Vikram Deshpande; Stephanie M Zimmerman; Gianmarco Contino; Brinda Alagesan; Michael R O'Dell; Lee B Rivera; Jay Harper; Scott Lonning; Rolf A Brekken; Nabeel Bardeesy
Journal:  Cancer Res       Date:  2012-07-11       Impact factor: 12.701

3.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

Authors:  Andrew J Aguirre; Nabeel Bardeesy; Manisha Sinha; Lyle Lopez; David A Tuveson; James Horner; Mark S Redston; Ronald A DePinho
Journal:  Genes Dev       Date:  2003-12-17       Impact factor: 11.361

4.  Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment.

Authors:  Vernon T Phan; Xiumin Wu; Jason H Cheng; Rebecca X Sheng; Alicia S Chung; Guanglei Zhuang; Christopher Tran; Qinghua Song; Marcin Kowanetz; Amy Sambrone; Martha Tan; Y Gloria Meng; Erica L Jackson; Franklin V Peale; Melissa R Junttila; Napoleone Ferrara
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

5.  Methylation of the SPARC gene promoter and its clinical implication in pancreatic cancer.

Authors:  Jun Gao; Jian Song; Haojie Huang; Zhaoshen Li; Yiqi Du; Jia Cao; Minghui Li; Shunli Lv; Han Lin; Yanfang Gong
Journal:  J Exp Clin Cancer Res       Date:  2010-03-26

Review 6.  The integrin-extracellular matrix axis in pancreatic cancer.

Authors:  John J Grzesiak; Jason C Ho; Abdool R Moossa; Michael Bouvet
Journal:  Pancreas       Date:  2007-11       Impact factor: 3.327

7.  BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.

Authors:  Bercin Kutluk Cenik; Katherine T Ostapoff; David E Gerber; Rolf A Brekken
Journal:  Mol Cancer Ther       Date:  2013-05-31       Impact factor: 6.261

8.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

9.  Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation.

Authors:  Shanna A Arnold; Lee B Rivera; Juliet G Carbon; Jason E Toombs; Chi-Lun Chang; Amy D Bradshaw; Rolf A Brekken
Journal:  PLoS One       Date:  2012-02-14       Impact factor: 3.240

10.  Structural basis of sequence-specific collagen recognition by SPARC.

Authors:  Erhard Hohenester; Takako Sasaki; Camilla Giudici; Richard W Farndale; Hans Peter Bächinger
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-14       Impact factor: 11.205

View more
  44 in total

1.  Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer.

Authors:  Victoria H Cruz; Emily N Arner; Wenting Du; Alberto E Bremauntz; Rolf A Brekken
Journal:  JCI Insight       Date:  2019-04-02

2.  Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases.

Authors:  Nuh N Rahbari; Dmitriy Kedrin; Joao Incio; Hao Liu; William W Ho; Hadi T Nia; Christina M Edrich; Keehoon Jung; Julien Daubriac; Ivy Chen; Takahiro Heishi; John D Martin; Yuhui Huang; Nir Maimon; Christoph Reissfelder; Jurgen Weitz; Yves Boucher; Jeffrey W Clark; Alan J Grodzinsky; Dan G Duda; Rakesh K Jain; Dai Fukumura
Journal:  Sci Transl Med       Date:  2016-10-12       Impact factor: 17.956

3.  Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells.

Authors:  Albert Lo; Liang-Chuan S Wang; Steven M Albelda; Ellen Puré; John Scholler; James Monslow; Diana Avery; Kheng Newick; Shaun O'Brien; Rebecca A Evans; David J Bajor; Cynthia Clendenin; Amy C Durham; Elizabeth L Buza; Robert H Vonderheide; Carl H June
Journal:  Cancer Res       Date:  2015-05-15       Impact factor: 12.701

4.  Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis.

Authors:  Zipeng Lu; Maximilian Weniger; Kuirong Jiang; Stefan Boeck; Kai Zhang; Alexander Bazhin; Yi Miao; Jens Werner; Jan G D'Haese
Journal:  Target Oncol       Date:  2018-08       Impact factor: 4.493

5.  Up-regulation of N-cadherin by Collagen I-activated Discoidin Domain Receptor 1 in Pancreatic Cancer Requires the Adaptor Molecule Shc1.

Authors:  Huocong Huang; Robert A Svoboda; Audrey J Lazenby; Jintana Saowapa; Nina Chaika; Ke Ding; Margaret J Wheelock; Keith R Johnson
Journal:  J Biol Chem       Date:  2016-09-07       Impact factor: 5.157

6.  Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival.

Authors:  Venkatrao Vantaku; Sri Ramya Donepudi; Danthasinghe Waduge Badrajee Piyarathna; Chandra Sekhar Amara; Chandrashekar R Ambati; Wei Tang; Vasanta Putluri; Darshan S Chandrashekar; Sooryanarayana Varambally; Martha K Terris; Kimberly Davies; Stefan Ambs; Roni Bollag; Andrea B Apolo; Arun Sreekumar; Nagireddy Putluri
Journal:  Cancer       Date:  2019-01-02       Impact factor: 6.860

7.  Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma.

Authors:  Kristina Y Aguilera; Huocong Huang; Wenting Du; Moriah M Hagopian; Zhen Wang; Stefan Hinz; Tae Hyun Hwang; Huamin Wang; Jason B Fleming; Diego H Castrillon; Xiaomei Ren; Ke Ding; Rolf A Brekken
Journal:  Mol Cancer Ther       Date:  2017-09-01       Impact factor: 6.261

8.  Fibulin-5 Blocks Microenvironmental ROS in Pancreatic Cancer.

Authors:  Miao Wang; Mary Topalovski; Jason E Toombs; Christopher M Wright; Zachary R Moore; David A Boothman; Hiromi Yanagisawa; Huamin Wang; Agnieszka Witkiewicz; Diego H Castrillon; Rolf A Brekken
Journal:  Cancer Res       Date:  2015-11-17       Impact factor: 12.701

Review 9.  The role of imaging in the clinical practice of radiation oncology for pancreatic cancer.

Authors:  Eugene J Koay; William Hall; Peter C Park; Beth Erickson; Joseph M Herman
Journal:  Abdom Radiol (NY)       Date:  2018-02

Review 10.  Matrix control of pancreatic cancer: New insights into fibronectin signaling.

Authors:  Mary Topalovski; Rolf A Brekken
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.